\
&
Contact us
The European Partnership for Personalised Medicine (EP PerMed) aims to align and promote regional and national priority setting and funding for research and implementation projects in the field of personalised medicine among the EU Member States, regions and beyond.
EP PerMed builds on over 15 years of EU-funded consortia, initiatives & events, but also on a wide range of national & European regional activities and efforts in all areas of the personalised medicine value continuum.
Grant Agreement negotiations for EP PerMed are ongoing. It is expected that the following Flemish partner organisations to participate in the Partnership:
| Belgium (Flanders) | Government of Flanders – Vlaams Gewest | https://www.vlaanderen.be/ |
| Belgium (Flanders) | Research Foundation – Flanders – Fonds Wetenschappelijk Onderzoek | https://www.fwo.be/en/ |
| Belgium (Flanders) | Flanders innovation & entrepreneurship – Fonds voor Innoveren en Ondernemen | https://www.vlaio.be/en |
Results will translate into delivery of better prevention and healthcare services, improved health outcomes for patients and citizens, and increased satisfaction with health systems.
Open & closed calls
A first joint transnational call for proposals under EP PerMed on "Identification or Validation of Targets for Personalised Medicine Approaches (PMTargets)" was launched in January 2024. The deadline for pre-proposals has passed. The result of the call for proposals is not expected before October 2024. First projects are expected to start end of 2024, beginning of 2025.
Information pages for stakeholders in Flanders:
- dedicated VLAIO webpage
- dedicated FWO webpage
You can register to EP PerMed's newsletter to be kept informed about future calls for proposals here.
Within EP PerMed, several earlier European Initiatives are joined under one roof. It will continue the activities of ERA PerMed in funding transnational innovation and research projects. In addition, EP PerMed will closely together with the International Consortium for Personalised Medicine ICPerMed for overarching strategic activities.
'ICPerMed Family' of Coordination and Support Actions:
Commission services: RTD-EP-PERSONALISED-MEDICINE@ec.europa.eu
The Partnership: eppermed@dlr.de
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
sarah.stroobants@fwo.be
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.